Germ Cell TumorNCT02099734
Germ Cell Tumor and Testicular Tumor DNA Registry
An observational study of Germ Cell Tumor and Testicular Tumor, run by Memorial Sloan Kettering Cancer Center at 8 sites in United States.
Trial summary
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Germ Cell Tumor, Testicular Tumor
- What is being tested?
- Questionnaires and sample of blood or saliva
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,000 participants
- Where
- 8 sitesUnited States
- Study dates
- Jan 2014to Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: At MSKCC, the following outpatient clinics will be used to recruit GCT and testicular tumor cases and controls: Urology (Department of Surgery), Gynecologic Oncology (Department of Surgery) Clinical Genetics, Genitourinary Oncology (Department of Medicine), and Gynecologic Medical Oncology (Department of Medicine).
Who may be able to join
- Case Cohort
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass
- Family Member Cohort
- Must be ≥ 18 years of age AND
Show all 14Show fewer
- Must be an English-speaker AND
- Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.
- Control Cohort
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND
- Must not have a family history of germ cell tumor or testicular tumor AND
- Must not be a blood relative of controls enrolled in this study
Who cannot join
None listed.
Trial locations and contacts
8 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Darren Feldman, MD contact
Zsofia Stadler, MD contact
8 sites in 1 country
United States8 sites, 8 recruiting
- Recruiting
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey
Darren Feldman, MD, 646-422-4491
- Not yet recruiting
Cold Springs Harbor Laboratory (Specimen Analysis)
Cold Spring Harbor, New York, 11724
Richard McCombie, PhD, 516-367-8800
- Recruiting
Memorial Sloan Kettering Commack
Commack, New York, 11725
Darren Feldman, MD, 646-422-4491
- Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Darren Feldman, MD, 646-422-4491
- Recruiting
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Darren Feldman, MD, 646-422-4491
- Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
Darren Feldman, MD, 646-422-4491
- Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Darren Feldman, MD, 646-422-4491
Darren Feldman, MD
- Not yet recruiting
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Darren Feldman, MD, 646-422-4491
About this study
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.
- Conditions
- Germ Cell Tumor, Testicular Tumor
- Being tested
- Questionnaires, sample of blood or saliva
- Keywords
- 14-016
- Medical subject headings
- Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnairesBehavioural
sample of blood or salivaOther
A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
| Study group | Role | What they receive |
|---|---|---|
| A: suspicion of germ cell tumor and/or a testicular mass | patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs, Receives: Behavioral: Questionnaires; Other: sample of blood or saliva | |
| B: family members of Group A | relatives of patients with GCTs or testicular tumors Receives: Behavioral: Questionnaires; Other: sample of blood or saliva | |
| C: healthy controls unrelated to Group A or B | healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors Receives: Behavioral: Questionnaires; Other: sample of blood or saliva |
What is being measured
The primary outcome is the main question the study is designed to answer.
creation of a Germ Cell Tumor and testicular tumor registry
We will collect clinical data including diagnosis date, pathology, family history, and risk factors in patients with GCT-TT.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2014 (estimated)
- Study startJan 2014
- Primary completionJan 2028 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Germ Cell TumorStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Darren Feldman, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02099734
- Sponsor's protocol ID
- 14-016
- Status last verified
- Nov 2026
- First submitted
- 26 Mar 2014
- Last updated
- 4 Nov 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Germ Cell Tumor and Testicular Tumor DNA Registry
- ClinicalTrials.gov ID
- NCT02099734
- Acronym / sponsor ID
- 14-016
- Conditions
- Germ Cell Tumor, Testicular Tumor
- Keywords
- 14-016
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- Jan 2014 (actual)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 31 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| A: suspicion of germ cell tumor and/or a testicular mass | – | Behavioral: Questionnaires, Other: sample of blood or salivapatients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs, |
| B: family members of Group A | – | Behavioral: Questionnaires, Other: sample of blood or salivarelatives of patients with GCTs or testicular tumors |
| C: healthy controls unrelated to Group A or B | – | Behavioral: Questionnaires, Other: sample of blood or salivahealthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- At MSKCC, the following outpatient clinics will be used to recruit GCT and testicular tumor cases and controls: Urology (Department of Surgery), Gynecologic Oncology (Department of Surgery) Clinical Genetics, Genitourinary Oncology (Department of Medicine), and Gynecologic Medical Oncology (Department of Medicine).
Key inclusion criteria (14 listed)
- Case Cohort
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass
- Family Member Cohort
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Questionnaires | Behavioural | A: suspicion of germ cell tumor and/or a testicular mass, B: family members of Group A, C: healthy controls unrelated to Group A or B |
| sample of blood or salivaA sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample. | Other | A: suspicion of germ cell tumor and/or a testicular mass, B: family members of Group A, C: healthy controls unrelated to Group A or B |
Primary outcome
creation of a Germ Cell Tumor and testicular tumor registry
Time frame: 5 years
We will collect clinical data including diagnosis date, pathology, family history, and risk factors in patients with GCT-TT.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Germ Cell Tumor
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Darren Feldman, MD contact
Zsofia Stadler, MD contact
Darren Feldman, MD principal investigator
Memorial Sloan Kettering Cancer Center
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Germ Cell Tumor and Testicular Tumor, run by Memorial Sloan Kettering Cancer Center at 8 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Darren Feldman, MD (646-422-4491), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
creation of a Germ Cell Tumor and testicular tumor registry (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.